Orexigen Diet Pill Victory Shows Being Last Pays Off

Orexigen Therapeutics Inc.’s success in winning the first U.S. panel recommendation for a long-sought prescription diet pill led its shares to almost double and shows the company benefited from its rivals’ earlier difficulties.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.